|
一种新药物或可帮助提高艾滋病治疗效果
2009年04月01日 16:20:00 来源：新华网
新华网伦敦４月１日电 一项新研究显示，那些用抗逆转录病毒疗法治疗没有效果的艾滋病病毒感染者，将来再结合用一种氨基酸药物进行治疗，或许可以显著改善他们的生存状态。
英国帝国理工学院等机构的研究人员１日在《免疫学杂志》上说，他们把一种名为Ｄ－１ｍＴ的氨基酸药物与抗逆转录病毒疗法结合使用，显著降低了猕猴体内的猿类免疫缺陷病毒ＳＩＶ的水平。ＳＩＶ是迄今已知与人类艾滋病病毒最接近的病毒。
目前，治疗艾滋病通常使用高效抗逆转录病毒疗法，俗称鸡尾酒疗法，但约有十分之一的艾滋病病毒感染者由于抗药性等因素，这种疗法对他们没有疗效。因此研究人员希望他们的新研究将来能提高鸡尾酒疗法的疗效。
研究人员在实验中共使用了１１只感染ＳＩＶ的猕猴，它们先接受鸡尾酒疗法，疗程至少４个月，结果其中只有３只体内的ＳＩＶ降到不可测的水平，另８只则不见疗效，ＳＩＶ依然保持较高水平。
研究人员接着让这８只猕猴每天服用一定剂量的Ｄ－１ｍＴ，并在第６天和第１３天时接受血液检测，结果发现，第６天时只剩下３只猕猴体内ＳＩＶ含量仍处于可测水平，第１３天时只剩下２只猕猴体内ＳＩＶ含量处于可测水平，且含量非常低。
此外，动物实验还证实，只使用Ｄ－１ｍＴ治疗感染ＳＩＶ的猕猴并没有疗效。研究人员表示，下一步他们将研究Ｄ－１ｍＴ是如何发挥功效的。
目前，一些研究小组正在进行初步临床试验验证Ｄ－１ｍＴ治疗癌症的安全性和功效。研究人员指出，如果试验证明Ｄ－１ｍＴ能安全运用于人体，预计他们最早将于５年内开始实施Ｄ－１ｍＴ治疗艾滋病的临床试验。
A new drug or treatment can help improve the effect of AIDS
April 1, 2009 16:20:00 Source: Xinhua
Xinhua London Electricity April 1, a new study shows that those with anti-retroviral therapy is not the effect of HIV-infected persons, the future combination of amino acids with a drug treatment, may be able to significantly improve their survival status.
British institutions such as the Imperial College researchers at Day 1, "Journal of Immunology", they put a known amino acid D-1mT antiretroviral drugs and combination therapy significantly reduced the apes monkeys in vivo immune SIV virus levels. SIV and human are so far known to the nearest HIV virus.
At present, the treatment of AIDS used by highly active antiretroviral therapy, commonly known as cocktail therapy, but about one-tenth of HIV because of drug resistance and other factors, such therapy does not effect them. So researchers hope that their new research will be able to enhance the efficacy of the cocktail.
The researchers used in the experimental CPC 11 monkeys infected with SIV, they receive the cocktail, at least 4 months of treatment, resulting in only one of three body reduced to unmeasurable levels of SIV, and the other eight are not efficacy, SIV is still maintain a high level.
The researchers then let the eight monkeys must take every day dose of D-1mT, and in the first 6 days and 13 days to receive blood tests and found that, 6 days only three monkeys SIV content is still in the body can be measured the level of the first 13 days there are only two monkeys SIV in vivo can be measured in the level of content, and content is very low.
In addition, animal experiments also confirmed that only the treatment of D-1mT monkeys infected with SIV and not efficacy. The researchers said the next step they will study how D-1mT exert effective.
At present, the Group a number of preliminary clinical trials underway to verify the treatment of cancer D-1mT the safety and efficacy. The researchers pointed out that if the tests prove the safety of D-1mT applied to the human body, they are expected to begin as early as 5 years will be the implementation of D-1mT clinical trials to treat AIDS.
|
